Evidence map›Paper›PMID 38375049›Full record

ArticleChinese herbal medicines2024

Anemoside B4 inhibits SARS-CoV-2 replication

Mingyue Xiao, Ronghua Luo, Qinghua Liang, Honglv Jiang, Yanli Liu, Guoqiang Xu, Hongwei Gao, Yongtang Zheng, Qiongming Xu, Shilin Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese herbal medicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Pesticide residue detection technology for herbal medicine: current status, challenges, and prospects.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mingyue XiaoCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Ronghua LuoKey Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China.
Qinghua LiangCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Honglv JiangCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Yanli LiuCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Guoqiang XuCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Hongwei GaoCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530000, China.
Yongtang ZhengKey Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China.
Qiongming XuCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Shilin YangCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Anemoside B4 (AB4), the most abundant triterpenoidal saponin isolated from Methods: The cytotoxicity of AB4 was evaluated using the Cell Counting Kit-8 (CCK8) assay. SARS-CoV-2 infected HEK293T, HPAEpiC, and Vero E6 cells were used for Results: The data showed that AB4 reduced the propagation of SARS-CoV-2 along with the decreased Nucleocapsid protein (N), Spike protein (S), and 3C-like protease (3CLpro) in HEK293T cells. Conclusion: Our results indicated that AB4 inhibited SARS-CoV-2 replication through the RLR pathways and moderated the RNA metabolism, suggesting that it would be a potential lead compound for the development of anti-SARS-CoV-2 drugs.

Indexed as

anemoside B4interferonquantitative proteomicsRNA metabolismSARS-CoV-2

Identifiers

PMID38375049
PMCPMC10874757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.